Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand

A Avihingsanon; GV Matthews; SR Lewin; P Marks; J Sasadeusz; DA Cooper; S Bowden; S Locarnini; GJ Dore; K Ruxrungtham

Journal article

Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand

A Avihingsanon, GV Matthews, SR Lewin, P Marks, J Sasadeusz, DA Cooper, S Bowden, S Locarnini, GJ Dore, K Ruxrungtham

AIDS Research and Therapy | BIOMED CENTRAL LTD | Published : 2012

DOI: 10.1186/1742-6405-9-6

Open access

Download PDF

Abstract

Background: Hepatic Flare (HF) after initiation of highly active antiretroviral therapy (HAART) in HIV-HBV coinfected individuals is well recognized but prospective data on predictors and subsequent outcome are limited.Methods: The Tenofovir in HIV-HBV coinfection study was a randomized clinical trial of HBV-active HAART including lamivudine and/or tenofovir in antiretroviral naïve HIV-HBV individuals in Thailand.Results: Early HF (EHF) was defined as ALT > 5 × ULN during the first 12 weeks. EHF was observed in 8 (22%) of individuals at a median of 56 days. 6/8 EHF cases were asymptomatic and resolved with HAART continuation, however one subject with underlying cirrhosis died following rapid..

View full abstract

University of Melbourne Researchers

Sharon Lewin Author

Joseph Sasadeusz Author

Related Projects (2)

IMPROVED HEALTH OUTCOMES FOR PEOPLE LIVING WITH HIV

Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complicat..

HIV-HBV CO-INFECTION

Morbidity and mortality secondary to liver disease is greatly increased in people co-infected with HIV and HBV compared to those infected wi..

Grants

Funding Acknowledgements

The Kirby Institute for infection and immunity in society is funded by the Australian Government Department of Health & Ageing and is affiliated with the Faculty of Medicine, The University of New South Wales. KR and Vaccine & Cellular Immunology Laboratory are partly funded by the Research-team Strengthening Grant, National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand. Other authors declare that they have no competing interests.